Cargando…
Pathologic response at the epicenter of the treatment decision-making process in Human Epidermal Receptor–Type 2 overexpressing (Her2+) Early Breast Cancer (EBC): Challenges and opportunities for financially-constrained healthcare systems
After more than two decades of intensive research, tremendous progress has been achieved in the management of Human Epidermal Receptor-2 overexpressing (Her2+) Early Breast Cancer (EBC). In the latest years, major clinical trials have explored the neoadjuvant scenario, in addition to the prognostic...
Autor principal: | Mano, Max S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724193/ https://www.ncbi.nlm.nih.gov/pubmed/33279792 http://dx.doi.org/10.1016/j.breast.2020.11.016 |
Ejemplares similares
-
On the epicenter of COVID-19 and the origin of the pandemic strain
por: Ruan, Yongsen, et al.
Publicado: (2022) -
Management of Amyloid Cardiomyopathy in Resource-Constrained Settings: Challenges and Opportunities
por: Singh, Suvir, et al.
Publicado: (2021) -
Was Wuhan the early epicenter of the COVID-19 pandemic?—A critique
por: Cao, Yanan, et al.
Publicado: (2022) -
How Brazil’s President turned the country into a global epicenter of COVID-19
por: Ferrante, Lucas, et al.
Publicado: (2021) -
Robust Guidelines for the Management of HR+ Her2− EBC: Crucial Value of CanAssist Breast
por: Vaid, Ashok, et al.
Publicado: (2022)